Mind Medicine (MindMed) (MNMD) — MindMed reported a Q2 2025 net loss of $42.7 million as R&D roughly doubled year-over-year to $29.8 million, reflecting three Phase 3 trials of MM120 ODT (LSD) in generalized anxiety disorder and major depressive disorder.
Cash and investments were $237.9 million at June 30, funding operations into 2027 and past the first Phase 3 topline. Voyage topline data was expected in the first half of 2026, with Panorama and Emerge to follow; the company also named Brandi L. Roberts as CFO.
Source: businesswire.com
For the rest of that week's sector news, read our week in review.